生物制剂与靶向合成改善病情抗风湿药对类风湿关节炎疲劳的影响
疲劳是类风湿关节炎常见且致残性症状,自2007年起被纳入核心结局指标。生物制剂和靶向合成改善病情抗风湿药的临床试验将疲劳作为次要终点,2016年Cochrane综述认为生物制剂对改善疲劳有中等效应,较新的sarilumab及托法替布、巴瑞替尼试验显示类似获益。疲劳改善是否由直接效应或炎症减轻介导尚不明确,且因疲劳为次要终点,许多分析未校正疼痛、情绪和贫血等混杂因素。
要点
- 疲劳是RA核心结局指标之一,生物制剂和靶向合成DMARDs临床试验显示对疲劳有改善作用。
- 2016年Cochrane综述结论为生物制剂对RA疲劳有中等效应。
- 疲劳改善机制不明,且分析多未校正疼痛、情绪和贫血等混杂因素。
核心结论
- 生物制剂和靶向合成DMARDs对RA患者疲劳有改善作用,但效应是否直接或通过炎症减轻介导尚不明确。
研究设计与样本
- 本文为综述,汇总了生物制剂和靶向合成DMARDs临床试验中疲劳作为次要终点的证据,包括2016年Cochrane综述及sarilumab、托法替布和巴瑞替尼的较新试验。
主要发现
- 2016年Cochrane综述结论为生物制剂对改善RA疲劳有中等效应。
- sarilumab及托法替布、巴瑞替尼的较新临床试验显示与既往生物制剂相似的疲劳改善获益。
临床怎么用
- 临床中可关注生物制剂和靶向合成DMARDs对RA患者疲劳的改善作用,同时注意评估疼痛、情绪和贫血等可能影响疲劳的因素。
局限性
- 疲劳多为次要终点,许多分析未校正疼痛、情绪和贫血等潜在混杂因素,是显著局限。
- 生物制剂和靶向合成DMARDs改善疲劳的机制尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fatigue is a common and debilitating symptom in patients with RA. Since 2007, fatigue has been included as one of the core outcome measures in RA. Clinical trials of biologic DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) have included fatigue as a secondary endpoint. A Cochrane review in 2016 concluded that the bDMARDs have a moderate effect on improving fatigue in RA. More recent clinical trials of the new biologic agent sarilumab and the Janus kinase inhibitors tofacitinib and baricitinib showed similar benefits. It remains unclear whether the effect of bDMARDs and tsDMARDs on fatigue is mediated by direct effects or through a reduction in inflammation. As fatigue was a secondary endpoint, many analyses did not adjust for potential confounding factors, including pain, mood and anaemia, which is a significant limitation.
引用
- Choy EH. Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis. Rheumatology (Oxford). 2019. PMID: 31682274. doi:10.1093/rheumatology/kez389
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。